Enrocin Flavoured Tablets 150 mg

Authorised

- Enrofloxacin

Product identification

Medicine name:
Enrocin Flavoured Tablets 150 mg

Active substance:
Enrofloxacin

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Enrofloxacin
150.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Withdrawal period by route of administration:

Oral use:

- **Dog**
  - Meat and offal. no withdrawal period — Not applicable.

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01MA90

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Belgium

Package description:
Lidding material: Plain 25-micron hard tempered Al foil coated with 7 GSM heat sealable lacquer Base foil & Forming foil: Multilayer cold form film (25-micron OPA/ 45-micron soft tempered Aluminum Foil/ 60-micron PVC film). 100 tablets.
Lidding material: Plain 25-micron hard tempered Al foil coated with 7 GSM heat sealable lacquer Base foil & Forming foil: Multilayer cold form film (25-micron OPA/ 45-micron soft tempered Aluminum Foil/ 60-micron PVC film). 50 tablets.
Lidding material: Plain 25-micron hard tempered Al foil coated with 7 GSM heat sealable lacquer Base foil & Forming foil: Multilayer cold form film (25-micron OPA/ 45-micron soft tempered Aluminum Foil/ 60-micron PVC film). 30 tablets.
Lidding material: Plain 25-micron hard tempered Al foil coated with 7 GSM heat sealable lacquer Base foil & Forming foil: Multilayer cold form film (25-micron OPA/ 45-micron soft tempered Aluminum Foil/ 60-micron PVC film). 20 tablets.
Lidding material: Plain 25-micron hard tempered Al foil coated with 7 GSM heat sealable lacquer Base foil & Forming foil: Multilayer cold form film (25-micron OPA/ 45-micron soft tempered Aluminum Foil/ 60-micron PVC film). 10 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic (abridged application) - art 13(1)

Marketing authorisation holder:
Felix Pharmaceuticals Private Limited

Marketing authorisation date:
7/11/2023

Manufacturing sites for batch release:
Wasdell Europe Limited

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V661940

Date of authorisation status change:
7/11/2023

Reference member state:
Portugal

Procedure number:
PT/V/0141/003

Concerned member states:
Belgium

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents